表纸
市场调查报告书

内分泌疗法药的全球市场:2020年~2024年

Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 356778
出版日期 内容资讯 英文 120 Pages
订单完成后即时交付
价格
Back to Top
内分泌疗法药的全球市场:2020年~2024年 Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024
出版日期: 2020年02月05日内容资讯: 英文 120 Pages
简介

全球内分泌疗法药市场在2020年~2024年的预测期间内,预计将以7%的年复合成长率增长,达到247亿8,000万美元的规模。内分泌障碍的发生率增加是市场成长主要因素之一。此外,肥胖与内分泌失调之间的联系有望推动市场增长。

本报告提供全球内分泌疗法药市场相关调查分析,提供市场规模及成长率,市场趋势,推动市场要素,课题,市场机会验证,再加上主要供应商等相关的系统性资讯。

目录

第1章 摘要整理

第2章 市场的状况

  • 市场生态系统

第3章 市场规模

  • 市场定义
  • 市场区隔分析
  • 市场规模(2019年)
  • 市场预测:2019-2024年的预测

第4章 波特的五力分析

  • 买主谈判力
  • 供应商谈判力
  • 新加入厂商的威胁
  • 替代品的威胁
  • 对手的威胁
  • 市场情况

第5章 市场区隔:各治疗领域

  • 糖尿病治疗药-市场规模与预测2019-2024
  • hGH-市场规模与预测2019-2024
  • 甲状腺荷尔蒙障碍-市场规模与预测2019-2024
  • 睾酮(睾丸激素)替代疗法-市场规模与预测2019-2024
  • 其他-市场规模与预测2019-2024

第6章 客户状况

第7章 各地区形势

  • 各地区市场区隔
  • 北美-市场规模与预测2019-2024
  • 欧洲-市场规模与预测2019-2024
  • 亚洲-市场规模与预测2019-2024
  • 其他地区-市场规模与预测2019-2024
  • 主要国家
  • 市场机会:各地区

第8章 成长要素,课题,及趋势

  • 市场成长要素
  • 市场课题
  • 市场趋势

第9章 供应商的展望

  • 概要
  • 业者情势
  • 形势的创新

第10章 供应商分析

  • 交易厂商
  • 供应商的市场定位
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc

第11章 附录

  • 调查范围
  • 美金的货币换算比率
  • 调查方法
  • 简称的清单

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: IRTNTR40785

Technavio has been monitoring the global endocrinology drugs market and it is poised to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders . In addition, association between obesity and endocrine disorders is anticipated to boost the growth of the global endocrinology drugs market as well.

Market Segmentation

Technavio's global endocrinology drugs market is segmented as below:

Therapy area

  • Diabetes Drugs
  • Thyroid Hormone Disorder Drugs
  • HGH
  • Testosterone Replacement Therapy
  • Others

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global endocrinology drugs market growth

This study identifies association between obesity and endocrine disorders as the prime reasons driving the global endocrinology drugs market growth during the next few years.

Prominent vendors in global endocrinology drugs market

We provide a detailed analysis of around 25 vendors operating in the global endocrinology drugs market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Eli Lilly and Co., GlaxoSmithKline Plc, Groupe Sanofi, Merck & Co. Inc., Novartis International AG, Novo Nordisk AS and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Diabetes drugs - Market size and forecast 2019-2024
  • hGH - Market size and forecast 2019-2024
  • Thyroid hormone disorders - Market size and forecast 2019-2024
  • Testosterone replacement therapy - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Other1 placement - Market share 2019-2024 (%)
  • 23.Comparison by Other1 placement
  • 24.Diabetes drugs - Market size and forecast 2019-2024 ($ billion)
  • 25.Diabetes drugs - Year-over-year growth 2019-2024 (%)
  • 26.hGH - Market size and forecast 2019-2024 ($ billion)
  • 27.hGH - Year-over-year growth 2019-2024 (%)
  • 28.Thyroid hormone disorders - Market size and forecast 2019-2024 ($ billion)
  • 29.Thyroid hormone disorders - Year-over-year growth 2019-2024 (%)
  • 30.Testosterone replacement therapy - Market size and forecast 2019-2024 ($ billion)
  • 31.Testosterone replacement therapy - Year-over-year growth 2019-2024 (%)
  • 32.Others - Market size and forecast 2019-2024 ($ billion)
  • 33.Others - Year-over-year growth 2019-2024 (%)
  • 34. Market opportunity by Other1
  • 35.Customer landscape
  • 36.Market share by geography 2019-2024 (%)
  • 37.Geographic comparison
  • 38.North America - Market size and forecast 2019-2024 ($ billion)
  • 39.North America - Year-over-year growth 2019-2024 (%)
  • 40.Europe - Market size and forecast 2019-2024 ($ billion)
  • 41.Europe - Year-over-year growth 2019-2024 (%)
  • 42.Asia - Market size and forecast 2019-2024 ($ billion)
  • 43.Asia - Year-over-year growth 2019-2024 (%)
  • 44.ROW - Market size and forecast 2019-2024 ($ billion)
  • 45.ROW - Year-over-year growth 2019-2024 (%)
  • 46.Key leading countries
  • 47.Market opportunity by geography ($ billion)
  • 48.Impact of drivers
  • 49.Impact of challenges
  • 50.Landscape disruption
  • 51.Industry risks
  • 52.Vendors covered
  • 53.Market positioning of vendors
  • 54.Abbott Laboratories - Overview (1/3)
  • 55.Abbott Laboratories - Overview (2/3)
  • 56.Abbott Laboratories - Overview (3/3)
  • 57.Abbott Laboratories - Business segments
  • 58.Abbott Laboratories - Key offerings
  • 59.Abbott Laboratories - Key customers
  • 60.Abbott Laboratories - Segment focus
  • 61.AbbVie Inc. - Overview (1/3)
  • 62.AbbVie Inc. - Overview (2/3)
  • 63.AbbVie Inc. - Overview (3/3)
  • 64.AbbVie Inc. - Business segments
  • 65.AbbVie Inc. - Key offerings
  • 66.AbbVie Inc. - Key customers
  • 67.AbbVie Inc. - Segment focus
  • 68.AstraZeneca Plc - Overview (1/3)
  • 69.AstraZeneca Plc - Overview (2/3)
  • 70.AstraZeneca Plc - Overview (3/3)
  • 71.AstraZeneca Plc - Product and service
  • 72.AstraZeneca Plc - Key offerings
  • 73.AstraZeneca Plc - Key customers
  • 74.AstraZeneca Plc - Segment focus
  • 75.Eli Lilly and Co. - Overview (1/3)
  • 76.Eli Lilly and Co. - Overview (2/3)
  • 77.Eli Lilly and Co. - Overview (3/3)
  • 78.Eli Lilly and Co. - Business segments
  • 79.Eli Lilly and Co. - Key offerings
  • 80.Eli Lilly and Co. - Key customers
  • 81.Eli Lilly and Co. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview (1/3)
  • 83.GlaxoSmithKline Plc - Overview (2/3)
  • 84.GlaxoSmithKline Plc - Overview (3/3)
  • 85.GlaxoSmithKline Plc - Business segments
  • 86.GlaxoSmithKline Plc - Key offerings
  • 87.GlaxoSmithKline Plc - Key customers
  • 88.GlaxoSmithKline Plc - Segment focus
  • 89.Groupe Sanofi - Overview (1/3)
  • 90.Groupe Sanofi - Overview (2/3)
  • 91.Groupe Sanofi - Overview (3/3)
  • 92.Groupe Sanofi - Business segments
  • 93.Groupe Sanofi - Key offerings
  • 94.Groupe Sanofi - Key customers
  • 95.Groupe Sanofi - Segment focus
  • 96.Merck & Co. Inc. - Overview (1/3)
  • 97.Merck & Co. Inc. - Overview (2/3)
  • 98.Merck & Co. Inc. - Overview (3/3)
  • 99.Merck & Co. Inc. - Business segments
  • 100.Merck & Co. Inc. - Key offerings
  • 101.Merck & Co. Inc. - Key customers
  • 102.Merck & Co. Inc. - Segment focus
  • 103.Novartis International AG - Overview (1/3)
  • 104.Novartis International AG - Overview (2/3)
  • 105.Novartis International AG - Overview (3/3)
  • 106.Novartis International AG - Business segments
  • 107.Novartis International AG - Key offerings
  • 108.Novartis International AG - Key customers
  • 109.Novartis International AG - Segment focus
  • 110.Novo Nordisk AS - Overview (1/3)
  • 111.Novo Nordisk AS - Overview (2/3)
  • 112.Novo Nordisk AS - Overview (3/3)
  • 113.Novo Nordisk AS - Business segments
  • 114.Novo Nordisk AS - Key offerings
  • 115.Novo Nordisk AS - Key customers
  • 116.Novo Nordisk AS - Segment focus
  • 117.Pfizer Inc. - Overview (1/3)
  • 118.Pfizer Inc. - Overview (2/3)
  • 119.Pfizer Inc. - Overview (3/3)
  • 120.Pfizer Inc. - Business segments
  • 121.Pfizer Inc. - Key offerings
  • 122.Pfizer Inc. - Key customers
  • 123.Pfizer Inc. - Segment focus
  • 124.Currency conversion rates for US$
  • 125.Research Methodology
  • 126.Validation techniques employed for market sizing
  • 127.Information sources
  • 128.List of abbreviations
Back to Top